GL1X · GenesisL1 explorer

Research workbench

Type IV secretion system effector protein bepa

Analyse Type IV secretion system effector protein bepa in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2VZA
Type
protein
Length
2,368 residues
Chains
8
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cell filamentation protein
UniProt
Q6G2A9
Ligands
SO4
Pockets
20 · best druggability 0.81

Structure

x-ray diffraction · 1 distinct chain · 46% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, C, D, E, F, G, HCell filamentation proteinprotein29646% helix, 11% strandQ6G2A9

Ligands and binding sites

  • SO4 · Sulfate ion · ion · 10 copies · chains A, B, C, D, E, F, G, H

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 12 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19980.810.8278SO4
28210.770.8159SO4
310840.770.7985SO4
410320.760.7877SO4
56070.690.7892SO4

Interfaces

10 interfaces between chains.

  • E–G · 1137 Ų buried · 13 hydrogen bonds · protein-protein
  • B–D · 1128 Ų buried · 13 hydrogen bonds · protein-protein
  • F–H · 1053 Ų buried · 13 hydrogen bonds · protein-protein
  • A–C · 1022 Ų buried · 10 hydrogen bonds · protein-protein
  • A–B · 628 Ų buried · 7 hydrogen bonds · protein-protein

Compared structures

  • 2VZA · Type IV secretion system effector protein BepA · the same entry in another collection · chain H against H, TM-score 1.00
  • Q6G2A9 · AlphaFold monomer V2.0 prediction for protein adenylyltransferase (Q6G2A9) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.